Clinical impact of Ocrelizumab dosing delays and their association with CD-19+ B-cell repletion during the COVID-19 pandemic
By Dr Nitin Sahi, Neurology SpR, University Hospitals of North Midlands NHS Trust
Poster
Write up
More MS Academy Medication Projects
Immunoglobulins levels in ocrelizumab therapy- UHS data
By Virginia Raluca Vasilescu, Clinical fellow in multiple sclerosis, University Hospitals Sussex NHS Foundation Trust
Reducing time to Disease-Modifying-Therapy initiation via homecare
By Sukhi Chahal, Advanced clinical pharmacist - MS & neurosciences, Oxford University Hospitals NHS Foundation Trust
Assessment of patients requiring an ‘’as needed treatment’’ with alemtuzumab therapy for resumed Multiple Sclerosis (MS) disease activity following the second dose of alemtuzumab from a single MS Centre in the North East of England
By Dr Alyaa H.A. Eissa, Neurology registrar ST5, Newcastle upon Tyne Hospitals NHS Foundation Trust
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.